CLINICAL TRIALS PROFILE FOR RALINEPAG
✉ Email this page to a colleague
Clinical Trials for Ralinepag
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT02279160 ↗ | Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension | Completed | Arena Pharmaceuticals | Phase 2 | The study was conducted as a placebo-controlled, randomized, 22-week double-blind study which included a dose titration period. An additional transition period occurred for those patients who elected to enroll into the open-label extension study, APD811-007. A total of 61 patients with PAH were enrolled. |
NCT02279160 ↗ | Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension | Completed | United Therapeutics | Phase 2 | The study was conducted as a placebo-controlled, randomized, 22-week double-blind study which included a dose titration period. An additional transition period occurred for those patients who elected to enroll into the open-label extension study, APD811-007. A total of 61 patients with PAH were enrolled. |
NCT02279745 ↗ | Long Term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension | Completed | Arena Pharmaceuticals | Phase 2 | This study is an open-label extension study to determine the long-term safety and tolerability of APD811 in patients with WHO Group 1 PAH who have completed the Phase 2 study, APD811-003. Patients must have completed the APD811-003 study and must meet eligibility criteria for APD811-007. |
NCT02279745 ↗ | Long Term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension | Completed | United Therapeutics | Phase 2 | This study is an open-label extension study to determine the long-term safety and tolerability of APD811 in patients with WHO Group 1 PAH who have completed the Phase 2 study, APD811-003. Patients must have completed the APD811-003 study and must meet eligibility criteria for APD811-007. |
NCT03626688 ↗ | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | Recruiting | Arena Pharmaceuticals | Phase 3 | Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH. |
NCT03626688 ↗ | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | Recruiting | United Therapeutics | Phase 3 | Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH. |
NCT03683186 ↗ | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | Enrolling by invitation | United Therapeutics | Phase 3 | Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Ralinepag
Condition Name
Clinical Trial Locations for Ralinepag
Trials by Country
Clinical Trial Progress for Ralinepag
Clinical Trial Phase
Clinical Trial Sponsors for Ralinepag
Sponsor Name